Company intelligence / Profile preview

i+Med

Vitoria-Gasteiz, Álava, Spainimedpharma.com ↗

Ownership: Private
Employees: ~100
Development stage: Commercial

Overview

i+Med specializes in the development of advanced nanohydrogel-based drug delivery platforms using its ADAPTEK® technology. The company partners with global pharma firms to develop customized solutions across more than 9 therapeutic areas and has experience bringing products from idea through clinical trials to market. Its own product line includes innovative treatments such as a hydrogel film for mouth ulcers that provides pain relief and promotes healing. No public clinical trial results are available due to the B2B/CDMO model.

Therapeutic areas: GastroenterologyOther
Modalities: NanohydrogelsBiopolymeric drug delivery systemsCoatingsMolecule carrier systems
Industry: Chemicals & Materials

Partnerships

Collaborates with leading pharmaceutical companies globally (>30 countries); specifics undisclosed

Beyond the preview

Go deeper on i+Med.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on i+Med.

Explore the full profile